We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHRM.L Regulatory News (PHRM)

  • There is currently no data for PHRM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Subscription & Operational Update

18 Jan 2016 07:00

RNS Number : 1110M
Phorm Corporation Limited
18 January 2016
 

18 January 2016

 

Phorm Corporation Limited

("Phorm" or the "Company")

Subscription to raise approximately US$1 million gross

and Operational Update

Phorm (AIM: PHRM), a leading advertising-technology company and first party data platform provider, is pleased to announce that it has raised approximately US$1 million before expenses via a subscription for 44,821,076 new ordinary shares of nil par value each in the capital of the Company (the "Subscription Shares") at a price of 1.55 pence per Subscription Share (the "Subscription").

Phorm intends to use the net proceeds raised from the Subscription for the group's general working capital purposes. The Subscription Shares will represent approximately 4.36 per cent. of the Company's enlarged issued share capital. The Subscription is conditional upon admission of the Subscription Shares to trading on AIM ("Admission").

The closing mid-market price of the Company's existing ordinary shares on 15 January 2016 (being the latest practicable business day prior to the date of this announcement) was 1.625 pence per share. Application will be made to the London Stock Exchange plc for the Subscription Shares to be admitted to trading on AIM. It is expected that Admission of the Subscription Shares will become effective and that dealings in the Subscription Shares will commence on AIM at 8.00 a.m. on 22 January 2016. The Subscription Shares will be fully paid and will rank pari passu in all respects with the Company's existing ordinary shares. Following Admission, the total issued ordinary share capital of the Company will comprise 1,028,089,892 ordinary shares.

Operational Update

Significant Reduction in Cash Burn Rate

In the Company's Interim Results for the six months to 30 June 2015, announced on 30 September 2015, Phorm stated that its monthly average cash burn rate was US$2.5 million per month for H1 2015 (representing a 31 per cent. decrease compared to H1 2014) which was targeted to be reduced to an average monthly cash burn rate of approximately US$1.3 million per month by December 2015.

 

Phorm is pleased to announce that, during Q4 2015, the Company identified and implemented additional significant cost savings, with a resultant average cash burn rate for H2 2015 of approximately US$1.5 million per month.

 

The Board is currently forecasting a further decrease in the Company's average cash burn rate to between US$0.63 million and US$0.71 million per month during 2016, with the forecast total cash requirement for 2016 being between US$7.5 million and US$8.5 million.

The anticipated reduction in the Company's cash burn rate is expected to be achieved through a combination of increased cash receipts from revenue growth, gross margin improvement and the implementation of further cost reductions.

 

Internet Service Provider ("ISP") Update

Phorm continues to be engaged in detailed discussions with several ISPs, in both the United States and Europe, which are at various stages. Recently, there have been noticeably increased levels of interest from certain ISPs in monetising their data by deploying such data to support ad serving. From the Company's discussions with ISPs, the Directors are confident in their belief that the Company's full service product set is unparalleled in the industry.

 

CBAN Business

Phorm's cookie based advertising network (CBAN) offering continues to ramp-up in the United States, through the Company's direct sales efforts, and in the United Kingdom via its channel partner, Insomnis Media.

 

In the United States marketplace, Phorm continues to expand its client list of major brands for which it is delivering advertising, with clients in the insurance, ISP and multiple systems operators, consumer electronic manufacturing and leisure sectors. The Company is also seeing traction in consumer packaged goods, and e-commerce and with large media planning and buying agencies.

 

Video

The Company has recently started to serve audiences for performance and video ad networks which, although currently still at an early stage, the Board believes has the potential to become a meaningful source of revenue during the 2016 financial year.

 

-Ends-

For further information please contact: 

Phorm Corporation Limited

Timothy Smith (Chief Executive Officer) +44 (0) 20 3397 6001

 

Mirabaud Securities LLP (Broker) +44 (0) 20 7321 2508

Jason Woollard 

Peter Krens

 

Strand Hanson Limited (Nominated Adviser) +44 (0) 20 7409 3494

James Harris Matthew Chandler James Dance

 

About Phorm:

Phorm is a leading advertising-technology and first party data platform provider that enables brands and publishers to address online users with personalised content and advertising. Phorm's innovative platform delivers a more interesting online experience for the user and addressable campaign results for marketers. For more information, please visit: www.phorm.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRMJTMBTBTFF
Date   Source Headline
26th Mar 20145:00 pmRNSIntention to raise £10 million
10th Mar 20147:01 amRNSMemorandum of Understanding with China Telecom
27th Jan 20147:00 amRNSCommercial Launch in China
20th Jan 20147:00 amRNSChange of Adviser
17th Jan 20147:00 amRNSAIM Rule 17 Disclosure Schedule Two (g) Update
6th Jan 20147:00 amRNSExercise of Employee Warrants for Shares
19th Nov 20137:00 amRNSOperational Update for Phorm China
19th Nov 20137:00 amRNSEquity Placing to raise £10 million
13th Nov 20137:12 amRNSStmnt re Share Price Movement
24th Oct 201311:16 amRNSOperations Update
3rd Oct 20137:00 amRNSOperational Launch in China
30th Sep 20137:00 amRNSInterim Results
27th Sep 20137:00 amRNSOperations Update
28th Aug 201312:43 pmRNSAGM Statement
7th Aug 201310:52 amRNSStmnt re Share Price Movement
6th Aug 20137:00 amRNSAGM Statement
26th Jul 20137:00 amRNSTR1: Notification of major interest in shares
26th Jul 20137:00 amRNSTR1: Notification of major interest in shares
17th Jul 20139:20 amRNSIssue of Equity
28th Jun 20137:20 amRNSAnnual Report and Financial Statements
28th Jun 20137:20 amRNSTurkish Operations Update
29th May 20137:00 amRNSFinancing Update
8th May 20138:34 amRNSHolding(s) in Company
23rd Apr 201310:18 amRNSPlacing to raise £7.15 million
21st Mar 20133:20 pmRNSStatement re Share Price Movement
20th Mar 20137:00 amRNSFinancing Update
24th Jan 20137:00 amRNSChinese and Turkish Operations Update
4th Jan 20137:00 amRNSIssue of Shares
18th Dec 20127:00 amRNSIssue of Shares
17th Dec 20127:00 amRNSTurkish Operational Update
13th Dec 20127:00 amRNSTR1: Notification of major interest in shares
21st Nov 201212:33 pmRNSResult of EGM & Admission to trading
6th Nov 201211:50 amRNS£6m Placing, Contract Signature & Turkey Update
16th Oct 20127:00 amRNSCommercial Progress Update
28th Sep 20127:00 amRNSInterim Results
20th Sep 20127:00 amRNSUpdate on Turkey and Phorm China Equity Fundraise
11th Sep 20127:00 amRNSAdmission to Trading
10th Sep 20123:33 pmRNSSch 1 Update - Phorm Corporation Limited
7th Sep 20122:58 pmRNSResults of EGM - Correction
7th Sep 201212:29 pmRNSResults of EGM
5th Sep 20124:15 pmRNSNotification of Major Interests in Shares
31st Aug 20123:49 pmRNSUpdated Appendix to Schedule 1
13th Aug 20129:06 amRNSSchedule 1 - Phorm Corporation Limited
13th Aug 20127:00 amRNSPhorm Re-Domicile of Holding Company from Delaware
2nd Aug 20127:00 amRNSPlacing
9th Jul 20127:00 amRNSCommencement of Commercial Activities with TTNET
3rd Jul 201210:14 amRNSTransfer of Shares
29th Jun 20127:00 amRNSAnnual Financial Report
19th Jun 20126:01 pmRNSCorrection: AGM Result
19th Jun 201211:29 amRNSAGM Result

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.